T
Thanyaphong Na Nakorn
Researcher at King Chulalongkorn Memorial Hospital
Publications - 11
Citations - 1159
Thanyaphong Na Nakorn is an academic researcher from King Chulalongkorn Memorial Hospital. The author has contributed to research in topics: Bortezomib & Panobinostat. The author has an hindex of 7, co-authored 11 publications receiving 1010 citations. Previous affiliations of Thanyaphong Na Nakorn include Chulalongkorn University.
Papers
More filters
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Paolo Corradini,Suporn Chuncharunee,Je-Jung Lee,Robert L. Schlossman,Tatiana Shelekhova,Kwee Yong,Daryl Tan,Tontanai Numbenjapon,Jamie Cavenagh,Jian Hou,Richard Leblanc,Hareth Nahi,Lugui Qiu,Hans Salwender,Stefano Pulini,Philippe Moreau,Krzysztof Warzocha,Darrell White,Joan Bladé,Wenming Chen,Javier de la Rubia,Peter Gimsing,Sagar Lonial,Jonathan L. Kaufman,Enrique M. Ocio,Ljupco Veskovski,Sang Kyun Sohn,Ming Chung Wang,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Claudia Corrado,Bourras Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +44 more
TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.
Journal ArticleDOI
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos,Fredrik Schjesvold,Fredrik Schjesvold,Meral Beksac,Roman Hájek,Katja Weisel,Hartmut Goldschmidt,Vladimir Maisnar,Philippe Moreau,Chang-Ki Min,Agnieszka Pluta,Wee Joo Chng,Martin Kaiser,Martin Kaiser,Sonja Zweegman,Maria-Victoria Mateos,Andrew Spencer,Shinsuke Iida,Gareth J. Morgan,Kaveri Suryanarayan,Zhaoyang Teng,Tomas Skacel,Antonio Palumbo,Antonio Palumbo,Antonio Palumbo,Ajeeta B Dash,Neeraj Gupta,Richard Labotka,S. Vincent Rajkumar,Daniel Bar,Alfredo Basso,Dorotea Fantl,Simon He,Neomi Horvath,Cindy Lee,Phillip Rowlings,Kerry Taylor,Tara Cochrane,Fiona Kwok,Sundreswran Ramanathan,Hermine Agis,Niklas Zojer,Alain Kentos,Fritz Offner,Jan Van Droogenbroeck,Ka Lung Wu,Angelo Maiolino,Gracia Martinez,Karla Zanella,Marcelo Capra,Sergio Eduardo Alonso Araujo,Evzen Gregora,Ludek Pour,Vlastimil Scudla,Ivan Spicka,Niels Abildgaard,Niels Holmark Andersen,Bo Amdi Jensen,Carsten Helleberg,Torben Plesner,Morten Salomo,Asta Svirskaite,Richard Delarue,Igor Wolfgang Blau,Aneta Schieferdecker,Veronica Teleanu,Markus Munder,Christoph Röllig,Han-Juergen Salwender,Stephan Fuhrmann,Katja Weisel,Jan Duerig,Matthias Zeis,Stefan Klein,Peter Reimer,Christian Schmidt,Christof Scheid,Karin Mayer,Martin Hoffmann,Markus Sosada,Athanasios Dimopoulos,Sosana Delimpasi,Mary-Christine Kyrtsonis,Achilleas Anagnostopoulos,Zsolt Nagy,Árpád Illés,Miklos Egyed,Zita Borbényi,Gabor Mikala,Najib Dally,Netanel Horowitz,Odit Gutwein,Anatoly Nemets,Iuliana Vaxman,Olga Shvetz,Svetlana Trestman,Rosa Ruchlemer,Arnon Nagler,Tamar Tadmor,Ory Rouvio,Meir Preis,Michele Cavo,Luca De Rosa,Pellegrino Musto,Anna Maria Cafro,Patrizia Tosi,Massimo Offidani,Alessandro Corso,Giuseppe Rossi,Anna Marina Liberati,Alberto Bosi,Kenshi Suzuki,Chiaki Nakaseko,Takayuki Ishikawa,Morio Matsumoto,Hirokazu Nagai,Kazutaka Sunami,Takaaki Chou,Koichi Akashi,Naoki Takezako,Shotaro Hagiwara,Hyeon Seok Eom,Deog-Yeon Jo,Jin Seok Kim,Jae Hoon Lee,Sung-Soo Yoon,Dok Hyun Yoon,Kihyun Kim,Mark-David Levin,Edo Vellenga,Monique C. Minnema,Anders Waage,Einar Haukås,Sebastian Grosicki,Andrzej Pluta,Tadeusz Robak,Herlander Marques,Rui Bergantim,Fernando Campilho,Wee Joo Chng,Yeow Tee Goh,Andrew McDonald,Bernado Rapoport,Miguel Angel Álvarez Rivas,Felipe de Arriba de la Fuente,Yolanda González Montes,Jesus Martin Sanchez,María-Victoria Mateos,Albert Oriol Rocafiguera,Laura Rosiñol,Jesús F. San Miguel,Jaime Pérez de Oteyza,Cristina Encinas,Adrian Alegre-Amor,Ana López-Guía,Per Axelsson,Kristina Carlson,Olga Stromberg,Markus Hansson,Cecile Hveding Blimark,Rouven Mueller,Chih-Cheng Chen,Ta-Chih Liu,Shang-Yi Huang,Po-Nan Wang,Thanyaphong Na Nakorn,Kannadit Prayongratana,Ali Ünal,Hakan Goker,Mehmet Sönmez,Sybiryna Korenkova,Aristeidis Chaidos,Heather Oakervee,Hamdi Sati,Reuben Benjamin,Ashutosh D. Wechalekar,Mamta Garg,Karthik Ramasamy,Gordon Cook,Andrew D Chantry,Matthew W Jenner,Francis K. Buadi,Robert Berryman,Murali Janakiram +183 more
TL;DR: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
Jesús F. San-Miguel,Vania Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert L. Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae H. Lee,Hermann Einsele,Monika Sopala,Bourras-Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +19 more
TL;DR: The overall survival benefit with panobinostat over placebo with bortezomib and dexamethasone was modest, however, optimisation of the regimen could potentially prolong treatment duration and improve patients' outcomes, although further trials will be required to confirm this.
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Guenther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Robert L. Schlossman,Jian Hou,Philippe Moreau,Sagar Lonial,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Bourras-Rezki Bengoudifa,Claudia Corrado,Florence Binlich,Jesús F. San-Miguel +20 more
TL;DR: This analysis demonstrated a clear PFS benefit of 7.8 months with PAN-BTZ-Dex among patients who received ≥2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis.
Journal ArticleDOI
Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma
Ponlapat Rojnuckarin,Thanyaphong Na Nakorn,Thamathorn Assanasen,Pongsak Wannakrairot,Tanin Intragumtornchai +4 more
TL;DR: The benefit of incorporating cyclosporin into the treatment regimen for SPTCL is suggested, with rapid improvement within weeks after oral cyclospora 4 mg/kg/day.